Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D00446 (
Sucralfate
)
278
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Inhibition of gastric acid secretion is a major factor in protecting the gastric mucosa, although other mechanisms such as bile salt binding may contribute to the protective properties of individual agents.
Sucralfate
, antacid (Maalox), and Meciadanol, a new flavonoid, were compared with cholestyramine resin for binding bile salts. The free, glycine, and taurine conjugates of the human bile salts, cholate, chenodeoxycholate, and deoxycholate, were incubated with each of the above.
Cholestyramine resin
adsorbed 91-97% of all bile salts tested. Meciadanol adsorbed all of the bile salts fairly well except for the free forms of chenodeoxycholate and deoxycholate. Meciadanol (53 to 84%) adsorbed bile salts better than sucralfate (4.2 to 61%), and significantly (P less than 0.05) better than Maalox (10 to 47%). In our in vitro studies, sucralfate was not as effective in binding bile salts as previously reported. Patients in the surgical intensive care unit were randomized prospectively to receive nasogastric instillation of Maalox, sucralfate, or Meciadanol to prevent gastrointestinal bleeding. The gastric aspirates were analyzed for bile salt concentration. The mean bile salt concentration of those treated with Maalox (0.24 mM), Meciadanol (0.24 mM), or sucralfate (0.35 mM) was significantly lower than those treated with nasogastric aspiration (0.87 mM) alone (P less than 0.01). This suggests that these substances bind bile salts and may provide additional protection to the gastric mucosa along with their ability to neutralize gastric acid.
...
PMID:Bile salt binding by maalox, sucralfate, and meciadanol: in vitro and clinical comparisons. 268 4
We have validated a method to measure bile salt binding by Maalox (aluminum hydroxide and magnesium hydroxide),
Carafate
(sucralfate), and
Questran
(cholestyramine) in vitro. The method used in this study involves a correction for adherent water volume and thus provides a correct measure of bile salt binding. With this approach, we described the binding properties of Maalox,
Carafate
, and
Questran
. The bile salt binding capacities of
Carafate
and Maalox are limited and do not have physiological or pharmacological significance. On the other hand, we found that
Questran
has substantial bile salt binding capacity. At the recommended dosage,
Questran
could deplete the total bile salt pool. We also found that
Carafate
, although not used as an antacid, has buffering capacity (maintaining a pH of solution in the range 4.2-4.8) which might contribute to its effectiveness as an ulcer treatment drug.
...
PMID:Bile salt binding properties of commonly used gastrointestinal drugs: maalox, carafate, and questran. 317 34